ANGPT2 and glioblastoma: Inhibition of VEGF and ANG-2 with ANG-2/VEGF antibodies (CrossMab, A2V) diminished vessel density and tumor growth, and induced prolonged survival compared to anti-VEGF antibody (B20) alone in mice bearing orthotopic syngeneic (Gl261) GBM or human (MGG8) GBM xenografts [233].